9.47
+0.83(+9.61%)
Currency In USD
| Previous Close | 8.64 |
| Open | 9.75 |
| Day High | 9.97 |
| Day Low | 8.85 |
| 52-Week High | 17.51 |
| 52-Week Low | 6.38 |
| Volume | 2.81M |
| Average Volume | 1.22M |
| Market Cap | 915.08M |
| PE | -18.57 |
| EPS | -0.51 |
| Moving Average 50 Days | 8.08 |
| Moving Average 200 Days | 11.22 |
| Change | 0.83 |
If you invested $1000 in Avadel Pharmaceuticals plc (AVDL) 10 years ago, it would be worth $582.05 as of May 08, 2025 at a share price of $9.47. Whereas If you bought $1000 worth of Avadel Pharmaceuticals plc (AVDL) shares 5 years ago, it would be worth $1,011.75 as of May 08, 2025 at a share price of $9.47.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Avadel Pharmaceuticals Announces Favorable Ruling in Appeal of Delaware Court Injunction
GlobeNewswire Inc.
May 06, 2025 4:30 PM GMT
- With this ruling, Avadel can seek and be granted FDA approval for LUMRYZ in Idiopathic Hypersomnia - - Federal Circuit decision permits new clinical trials and further development of LUMRYZ™ for the treatment of indications beyond narcolepsy - DUB
Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2025 Financial Results on May 7
GlobeNewswire Inc.
Apr 30, 2025 12:00 PM GMT
DUBLIN, Ireland, April 30, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at
Avadel and nference Announce Publication of Real-World Data on Sodium Oxybate Treatment Patterns in the Journal of Clinical Neuroscience
GlobeNewswire Inc.
Apr 17, 2025 12:00 PM GMT
-- Retrospective analysis reveals no significant differences in comorbidities in narcolepsy patients treated vs. not treated with sodium oxybate -- -- One third of patients taking immediate-release, twice-nightly sodium oxybate discontinued treatment